206-838-5110 ext. 102 general@etubics.com

Press Releases

Etubics Adds Caskey, Paessler, Zeldis to Leadership Boards

SEATTLE – (July 20, 2015) - Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, has added Dr. Thomas Caskey to its Board of Directors and Drs. / Jerome Zeldis, Slobodan Paessler to its Scientific...

Etubics Will Present Results of its Colorectal Cancer Phase 1 and 2 Immunotherapy Trial at the Annual American Society of Clinical Oncology Meeting In Chicago

Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting “active” immune response against diseases, will present clinical data from its Phase 1/2 proof of concept clinical trials using an immunotherapeutic to treat patients

Archives

Media Contact:

Jen Hodson
NantWorks
562-397-3639
Press@NantHealth.com